Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhaoke Ophthalmology Limited
兆 科 眼 科 有 限 公 司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)

(Stock Code: 6622)

VOLUNTARY ANNOUNCEMENT
INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by the board of directors (the "**Board**") of Zhaoke Ophthalmology Limited (the "**Company**") on a voluntary basis.

The Board hereby announces that the Board has approved a share repurchase plan for a period of twelve months, with an aggregate repurchase amount of no more than HK$100 million (the "**Share Repurchase Plan**"). The Share Repurchase Plan will be implemented by the Board pursuant to the general mandate to repurchase shares of the Company (the "**Shares**") granted to the Board by the shareholders of the Company (the "**Shareholders**") by way of an ordinary resolution passed at the annual general meeting of the Company held on May 15, 2026 (the "**Repurchase Mandate**").

Pursuant to the Repurchase Mandate, the Company is allowed to repurchase its own Shares up to 10% of the total number of Shares in issue as of the date of passing of the relevant resolutions granting the Repurchase Mandate (i.e. 54,874,901 Shares).

The Company will conduct the share repurchase in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), the Codes on Takeovers and Mergers and Share Buy-backs (the "**Takeovers Code**"), the Companies Act of the Cayman Islands, and all applicable laws and regulations to which the Company is subject. The Board has no intention to exercise the Repurchase Mandate to the extent that would result in the number of Shares in the hands of the public falling below the minimum percentage as prescribed by the Stock Exchange or give rise to an obligation to make a general offer to the Shareholders under the Takeovers Code. Shares repurchased pursuant to the Repurchase Mandate will be cancelled in due course.

The Company has taken into account various factors when formulating the Share Repurchase Plan, including its business outlook, operating performance, financial position and future profitability. The Board is of the view that the implementation of the Share Repurchase Plan demonstrates its confidence in the Group's business outlook and prospects and will help create long-term value for the Shareholders. The Company intends to fund the share repurchases using its internal resources.

Shareholders and potential investors of the Company are advised that the implementation of the Share Repurchase Plan will be subject to market conditions and will be at the absolute discretion of the Board. The Company does not guarantee the timing, quantity, or price of any share repurchases. Shareholders and potential investors are advised to exercise caution when trading the Company's securities.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, June 8, 2026

As at date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.